PCDHGC3

Across TCGA pan-cancer cohorts, PCDHGC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCDHGC3 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCDHGC3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHGC3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where PCDHGC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.214	0.797	.002	44	view →
PDAC	DFS	Quartile	All	0.221	0.748	.002	34	view →
LSCC	DFS	Tertile	All	0.338	0.911	.019	4	view →
GBM	OS	Quartile	All	0.808	0.948	.031	2	view →
HNSC	DFS	Median	II,III,IV	0.970	0.878	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCDHGC3–LUAD (DFS)

Open the LUAD breakdown →